May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Effects of Brimonidine, Timolol, and Fixed Combination Brimonidine-Timolol on FcER1 Stimulated Human Mast Cells
Author Affiliations & Notes
  • G. Galatowicz
    Clinical Ophthalmology, Institute of Ophthalmology, UCL, London, United Kingdom
  • V. Chan
    Clinical Ophthalmology, Institute of Ophthalmology, UCL, London, United Kingdom
  • M. E. Stern
    Allergan Inc., Irvine, California
  • V. L. Calder
    Clinical Ophthalmology, Institute of Ophthalmology, UCL, London, United Kingdom
  • Footnotes
    Commercial Relationships G. Galatowicz, None; V. Chan, None; M.E. Stern, Allergan Inc., E; V.L. Calder, Allergan Inc., F; Allergan Inc., C.
  • Footnotes
    Support Allergan; Fight for Sight UK
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 2305. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G. Galatowicz, V. Chan, M. E. Stern, V. L. Calder; Effects of Brimonidine, Timolol, and Fixed Combination Brimonidine-Timolol on FcER1 Stimulated Human Mast Cells. Invest. Ophthalmol. Vis. Sci. 2007;48(13):2305.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: The IOP-lowering fixed combination of brimonidine/timolol has been reported to be associated with a lower rate of ocular allergy as compared with brimonidine alone. The aim of this study was to examine the effects of brimonidine, timolol or a combination on resting and FcεR1- activated human mast cells in vitro.

Methods:: Human cord blood CD34+stem cells (CBMC; 105) were expanded in StemspanTM medium with SCF [100ng/mL], IL-6 [50ng/mL] and IL-3 [1ng/mL] during the first 14 days. At week 11, differentiation was confirmed by expression of CD117 (c-kit) and FcεR1. Unstimulated CBMC (106 cells/mL) were cultured either alone or in the presence of brimonidine [0.01 - 0.0001%], timolol [0.025 - 0.00025%] or a combination of both. For activation, CBMC were incubated with 4µg/ml IgE for 16 hr, with drug combinations given 30 min before adding 25µg/ml anti-IgE Ab. Culture supernatants were harvested at 1hr for histamine determination by ELISA. After 24 hr, cells were stained for intracellular expression of TNFα and IL-4, and analyzed by flow cytometry.

Results:: Histamine levels were low in unstimulated cells [9.9 ± 0.7 ng/mL] and were unaffected by the drugs. After FcεR1 stimulation, histamine levels were increased [36.6 ± 2.1 ng/mL; P<0.02] relative to control. Timolol decreased levels of histamine at the lowest concentration [0.00025%; P<0.03] whereas brimonidine increased histamine levels, although this failed to reach significance (P=0.052). The combination of drugs decreased histamine levels to those of controls. Under resting conditions, 100% CBMC were IL-4+ and less than 30% were TNFα+. Brimonidine, timolol and the combination of brimonidine and timolol had little or no effect on IL-4 or TNFα expression at 24 hr in resting or activated CBMC.

Conclusions:: Resting CBMC were unaffected by the drugs. Timolol was selectively inhibitory for histamine secretion by stimulated CBMC. The brimonidine-mediated upregulation of histamine was reduced in the presence of timolol.

Keywords: conjunctiva • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×